Navigation Links
Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development
Date:3/11/2008

STRASBOURG, France, March 11 /PRNewswire-FirstCall/ -- Transgene (Euronext Paris: FR0005175080) announces today its achievements in operations, financial performance for 2007 and outlook for 2008.

"2007 was a breakthrough year for Transgene, marked by two major accomplishments: the signing of a partnership agreement with Roche in the domain of therapeutic vaccines for the treatment of diseases caused by the HPV virus, and the successful completion of a EUR100.1m capital increase on European markets," declared Philippe Archinard, Managing Director of Transgene.

Key financial highlights include:

- Total revenues for the year were EUR28million compared to EUR5.5m in 2006.

- Transgene closed the year with a net loss of EUR5.5m compared to a net loss of EUR22m a year earlier.

- Basic loss per ordinary share was EUR0.28 versus EUR1.41 in 2006.

- Research and development expenditures were EUR28.8m compared to EUR24.2m in 2006.

- In 2007, net cash expenditure, excluding capital increase, was EUR5.5m compared to EUR20.7m in 2006.

- At the end of 2007, the company held cash and cash equivalents of EUR111.3m, which should enable it to finance some four years of operating costs.

Major Accomplishments of 2007:

Partnership Roche /Transgene: announced in April 2007, an exclusive world wide license agreement aimed at the development, registration and commercialisation of Transgene's therapeutic vaccines developed to fight diseases caused by the Human Papilloma Virus. Transgene received an upfront payment and a regulatory milestone of EUR23m in June 2007 and may receive further payments of up to EUR195m covering clinical development milestones and commercial milestones based on future sales of HPV products, stemming from Transgene's research. Under the terms of the agreement, Transgene is also entitled to receive progressive, double digit royalties on all future sales.

Strengthening of the Equity Bas
'/>"/>

SOURCE Transgene S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
2. Transgene: Cash Position of EUR 119 Million as of September 30, 2007
3. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
4. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
5. Medline and 3M Agree to Strategic Partnership in Electrosurgery
6. Partnership With SearchMedica.com to Enhance Web Searches on ModernMedicine.com
7. B-Line Medical and Immersion Medical Announce Partnership
8. Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference
9. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
10. ExonHit and bioMerieux Amend Their Strategic Partnership
11. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... Dec. 22, 2014 GenomeDx Biosciences today announced ... Cancer Classifier, a genomic test for prostate cancer, was ... men managed by radical prostatectomy without adjuvant therapy. Although ... relatively uncommon, using tumor genomics to identify these men ... is an important advance. The study has been ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... Md., Aug. 13 PharmAthene, Inc.,(Amex: PIP ... against biological and chemical threats, announced today,that proceedings ... to,affirm the validity of the merger between Healthcare ... Court of Chancery will determine that the Merger ...
... San Francisco Office Doubles Staff; San Diego Office to Offer Regulatory ... ... Image Solutions, Inc. (ISI), a,leader in providing software and services to ... Francisco,office and opening of a new facility in San Diego. The ...
... Addressing Increased Demand for Food, Feed, Fuel, Materials, ... (NYSE: DD ),Chairman and CEO Charles O. ... Thomas M. Connelly, and Group Vice President -- ... investors on DuPont,businesses serving the agriculture and biofuels ...
Cached Biology Technology:Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court 2ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 2ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 3ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 4DuPont Leaders Brief Investors on Agriculture Businesses 2DuPont Leaders Brief Investors on Agriculture Businesses 3
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... , Construction of ENJOY: A Generation House, the U.S. Department ... a collaborative effort of Rutgers, The State University of New ... following a recent ground-breaking at NJIT. Once construction of ... topping-off event at NJIT with major sponsors and VIP guests. ...
... (Boston) Kenneth Walsh, PhD, FAHA, the Aram ... of the Whitaker Cardiovascular Institute at Boston University ... 2011 American Heart Association (AHA) Distinguished Scientist. The ... The AHA created a Distinguished Scientist designation ...
... University biologists identified a new way in which bacteria hijack ... new antibiotics. Zhao-Qing Luo, the associate professor of biological ... new enzyme used by the bacterium Legionella pneumophila ... cell in order to take up residence. "Legionnaires, disease ...
Cached Biology News:Team New Jersey to make precast concrete solar house reality 2BUSM professor selected as American Heart Association Distinguished Scientist 2Purdue biologists identify new strategy used by bacteria during infection 2Purdue biologists identify new strategy used by bacteria during infection 3
Request Info...
... service provides the premium quality siRNAs you ... siRNAs can be readily ordered online by ... or by providing the sense and antisense ... Validated and Silencer Pre-designed siRNAs, which are ...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Biology Products: